SCHEMBL3584527

SCHEMBL3584527

NS(=O)(=O)N=C1NCC(c2cccc(Oc3cnccn3)c2)N1c1ccc(Cl)cc1

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.39
SLC6A4 P31645 2/20 0.39
SLC6A3 Q01959 2/20 0.39
GAA P10253 1/20 0.36
ALDH1A1 P00352 2/20 0.35
MAPT P10636 1/20 0.35
CA1 P00915 3/20 0.34
CA2 P00918 3/20 0.34
CA9 Q16790 3/20 0.34
CA12 O43570 2/20 0.34
HRH3 Q9Y5N1 1/20 0.33
LMNA P02545 1/20 0.33
P2RX3 P56373 4/20 0.31
FAAH O00519 1/20 0.31
MAOA P21397 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3584520 1.00 SLC6A2 (0.39) SLC6A2SLC6A4SLC6A3GAAALDH1A1
SCHEMBL13168423 1.00 SLC6A2 (0.39) SLC6A2SLC6A4SLC6A3GAAALDH1A1
SCHEMBL3593214 0.92 ALDH1A1 (0.37) SLC6A2SLC6A4SLC6A3GAAALDH1A1
SCHEMBL3593208 0.92 ALDH1A1 (0.37) SLC6A2SLC6A4SLC6A3GAAALDH1A1
SCHEMBL3593210 0.92 ALDH1A1 (0.37) SLC6A2SLC6A4SLC6A3GAAALDH1A1
SCHEMBL3582511 0.85 SLC6A2 (0.39) SLC6A2SLC6A4SLC6A3GAAALDH1A1
SCHEMBL3582513 0.85 SLC6A2 (0.39) SLC6A2SLC6A4SLC6A3GAAALDH1A1
SCHEMBL4447667 0.82 SLC6A2 (0.38) SLC6A2SLC6A4SLC6A3GAAALDH1A1
SCHEMBL3583868 0.82 FAAH (0.40) SLC6A2SLC6A4SLC6A3GAAALDH1A1
SCHEMBL3583863 0.82 FAAH (0.40) SLC6A2SLC6A4SLC6A3GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130210769-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY IRM LLC (BM) 2013-08-15 US claimed
US-20100234365-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY IRM LLC (BM) 2010-09-16 US claimed
US-20130210769-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY IRM LLC (BM) 2013-08-15 US disclosed
US-8431607-B2 Compounds and compositions as inhibitors of cannabinoid receptor 1 activity IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) 2013-04-30 US disclosed
US-20100234365-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY IRM LLC (BM) 2010-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130210769-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY CNR1, CNR2, FAAH SLC6A2 3123/4885SLC6A4 2606/4885SLC6A3 2495/4885
US-20100234365-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY CNR1, CNR2, FAAH SLC6A2 3123/4885SLC6A4 2606/4885SLC6A3 2495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.